 Dave Mazza, welcome back to TFNN, great day to have you. Yes, certainly, Tom. Nice to be back. Absolutely. So, hey, we got us, you know, and folks, I took this right off the direction website. I think we're going to start here, Dave. You know, the bottom line, I mean, the market goes top side today in a big way. You know, great news on the vaccine front, no doubt. And I know that, you know, bottom line, you get a lot of different ETFs inside the biotech space. So, let's talk about it. Yeah, so we do. So, for the traders out there, you know, we have two biotech ETFs, LabB and LabD. And look today, Tom, like all of our lineup, it doesn't really matter if we're talking energy, financials. The biotechs, as you just asked about, we're seeing a massive increase in volume today because this is some of the biggest divergence in performance that we've seen across various sectors, really going, this year going back to March, if not, in some cases, you know, biggest ever divergences performance-wise, looking at index data, you know, going back decades. Yes. And you know, folks, when we talk the triples with direction with Dave, it's important to understand, and they, you know, they educate each and every day, that these are daily investment vehicles. And you can see, like a day like today, this has been a trade-as-paradise, Dave, no doubt, for, you know, traders that are out here, because when you had folks that said, yeah, we had the S&Ps up 160, you get down to 90, we're at 100 right now. And so let's talk a little bit about the S&Ps, your leveraged products there, and the NQs and leveraged products there, because you just, as you said, the divergence out here is amazing today, right? Yes. So really what we're seeing kind of from a thematic perspective is a reversal in much of the momentum that was in kind of your high secular growth names, really embodied by the NASDAQ. But those are your tech, your consumer discretionaries, and a reversal into areas that have been out of favour. So whether that's small caps, financials, energy in particular, you know, names that have been beaten down, because of course the vaccine is a great sign, not just for humanity and everyone's health, but for these areas of the market that had tons of question marks out there. So yet today, of course, we're seeing massive performance in our three X vehicles, or two X vehicles, again for traders to take advantage of those moves on a daily basis. So not long-term, they shouldn't be intended to be long-term holdings in any way, shape, or form, but if you're a trader and want to take advantage of the moves in the S&P 500 on the positive side, that's SPXL. And then if you want to take the contrarian view, which actually we're seeing today, at least in flows, a lot of money is moving into SPXS. People may be setting up for tomorrow a bit of a reversal, which is sort of interesting. Now folks, what Dave just said here, this is so cool and you can go to their website every night and it'll show you where the flows are going, because there's no doubt, you know, and the morning show, Dave, I was talking about the aspect is that it's really hard to comprehend sometimes that you get a market that goes dramatically higher and then, depending on how long people have been in the market, you know, those S&Ps, I mean, they went down 45 points pretty quick off the high. And like when you go back, whether it's, I'm not quite sure, when it had sell the news, but that is, you know, that is really hard to comprehend when you're kind of a new trader, right? I mean, it's like, okay, well, this should go up 200 S&P points instead of 150. Yeah, well, you know, if you were to open up your textbook, you know, for undergrad finance or your MBA, these moves should theoretically be priced into the markets, right? Yes. And we know at some point a vaccine is going to come, whenever that's going to come, we don't know. And still there's question marks of exactly, again, all good news, but question marks of one that's actually going to be able to be distributed if it's 2Q, 3Q. But the market's supposed to be a discounting mechanism, right? Yeah. So investors are now discounting the potential for those earnings to be a lot better than what they were. But what I would say, again, the opportunity for traders here is, you know, look, unfortunately, the COVID case count, hospitalizations death count are still rising here in the short term. So there's gonna, I think, still be a lot of volatility out there. Again, which is one of the reasons, you know, one of our newer ETFs is focused on the S&P 500 high beta index. This is a bull and bear pair. So these are, this is 100 highest beta names in the S&P 500. What we're seeing today is tons of action in both sides. Yes. HIVL, which is the bull, and then HIVS, which is the bear, because in this basket, again, we're seeing traders take both opinions today, even though it's significantly outperforming, of course, on the long side. These are all of your names that have been